+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Recombinant Uricase Market by Product Type (Biosimilars of Recombinant Uricase, Non-Pegylated Uricase, Pegylated Uricase), Route Of Administration (Intramuscular, Intravenous, Subcutaneous), Application, End-User - Global Forecast 2025-2030- Product Image
Recombinant Uricase Market by Product Type (Biosimilars of Recombinant Uricase, Non-Pegylated Uricase, Pegylated Uricase), Route Of Administration (Intramuscular, Intravenous, Subcutaneous), Application, End-User - Global Forecast 2025-2030- Product Image
Sale

Recombinant Uricase Market by Product Type (Biosimilars of Recombinant Uricase, Non-Pegylated Uricase, Pegylated Uricase), Route Of Administration (Intramuscular, Intravenous, Subcutaneous), Application, End-User - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 181 Pages
  • March 2025
  • Region: Global
  • 360iResearch™
  • ID: 6055656
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Recombinant Uricase Market grew from USD 1.44 billion in 2024 to USD 1.53 billion in 2025. It is expected to continue growing at a CAGR of 5.94%, reaching USD 2.04 billion by 2030.

The recombinant uricase market has experienced considerable growth and transformation over recent years, spurred by breakthroughs in biotechnology and an increasing demand for innovative therapeutic solutions. Advances in genetic engineering and protein synthesis are reshaping treatment avenues, ultimately expanding the boundaries of what is possible in managing conditions associated with uric acid imbalances. With rising incidences of gout and other hyperuricemic conditions, stakeholders are placing renewed focus on the development of more effective enzyme replacement therapies.

In this competitive landscape, industry participants are not only investing heavily in research and development but are also continually refining their production processes, which has led to improved safety profiles and treatment outcomes. As global health challenges evolve, the recombinant uricase market stands out for its potential to change the way chronic and acute conditions, such as various forms of gout, are managed worldwide.

This report provides an in-depth overview of the driving forces within the market, shedding light on dynamic trends, evolving regional perspectives, and the strategic initiatives adopted by industry leaders. The following sections detail how technological advancements and regulatory reforms have influenced market structure, segmentation strategies, and competitive positioning, thereby setting the stage for future developments in this revolutionary therapeutic domain.

Transformative Shifts in the Landscape

Recent years have marked a period of profound change within the recombinant uricase market, with transformative shifts redefining competitive strategies and technological adoption. Innovations in molecular design and process optimization have led to enhanced production techniques, while regulatory bodies have updated their compliance frameworks in response to novel biopharmaceutical modalities. These factors have significantly altered how products are developed and brought to market.

Market participants have embraced these transformative trends by investing in state-of-the-art research facilities and by fostering collaborations with academic institutions and biotech innovators. The convergence of advanced analytics, personalized medicine, and improved patient monitoring technologies has not only optimized clinical trials but has also accelerated the pathway from laboratory research to commercial application. Furthermore, the evolving payer landscape and reimbursement strategies have driven manufacturers to focus on the cost-effectiveness of these innovative therapeutics.

As competitors recalibrate their business models to address both emerging challenges and new opportunities, the importance of agility and adaptive strategic planning becomes increasingly clear. Stakeholders now must consider a multifaceted approach that incorporates the latest technological developments, market consolidation trends, and evolving regulatory requirements to remain ahead in this competitive and fast-paced environment.

Key Segmentation Insights

An in-depth examination of the recombinant uricase market reveals significant segmentation across various dimensions, each offering unique insights into market behavior and consumer needs. The segmentation based on product type highlights diverse offerings including biosimilars of recombinant uricase, non-pegylated uricase, and pegylated uricase, each catering to different therapeutic performance profiles and patient requirements. Further complexity is introduced with segmentation by the route of administration, which examines the nuances between intramuscular, intravenous, and subcutaneous methods, thereby influencing patient convenience and efficacy outcomes.

Moreover, an analysis of application-based segmentation demonstrates that the market addresses critical treatment areas such as cancer treatment, gout treatment, kidney diseases, neurological disorders, and rare genetic disorders. Within this cluster, gout treatment itself undergoes further segmentation into chronic gout, hyperuricemia, refractory gout, and tumor lysis syndrome, ensuring that therapy is finely tuned to the severity and specifics of individual conditions. Additionally, segmentation by end-user lays out a framework that includes healthcare providers, pharmaceutical manufacturers, and research and development institutes, with a closer look at how healthcare providers operate within clinics, dialysis centers, and hospitals. Each segmentation dynamic contributes to a more granular understanding of market preferences, competitive gaps, and future growth trajectories.

Based on Product Type, market is studied across Biosimilars of Recombinant Uricase, Non-Pegylated Uricase, and Pegylated Uricase.

Based on Route Of Administration, market is studied across Intramuscular, Intravenous, and Subcutaneous.

Based on Application, market is studied across Cancer Treatment, Gout Treatment, Kidney Diseases, Neurological Disorders, and Rare Genetic Disorders. The Gout Treatment is further studied across Chronic Gout, Hyperuricemia, Refractory Gout, and Tumor Lysis Syndrome.

Based on End-User, market is studied across Healthcare Providers, Pharmaceutical Manufacturers, and Research & Development Institutes. The Healthcare Providers is further studied across Clinics, Dialysis Centers, and Hospitals.

Key Regional Insights

The geographic distribution of recombinant uricase market activities underscores the importance of embracing diverse regional dynamics. Market trends differ markedly between regions such as the Americas, Europe, Middle East & Africa, and Asia-Pacific, where varying regulatory environments, economic conditions, and healthcare infrastructures drive distinct strategic imperatives. In the Americas, factors like high healthcare expenditure and robust research initiatives have expedited market development. Meanwhile, in Europe, Middle East & Africa, collaborative efforts between public institutions and private enterprises are paving the way for accelerated market adoption.

The Asia-Pacific region, characterized by its rapid urbanization and expanding middle-class population, presents significant opportunities fueled by increased investment in healthcare infrastructure and innovation. These regional insights provide a roadmap that allows stakeholders to tailor their approaches by aligning product innovation, commercial strategies, and market entry plans with geographical realities and consumer behavior trends.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Key Companies Insights

Major industry players have become the cornerstone of the recombinant uricase market, each bringing specialized expertise and a commitment to innovative therapeutic approaches. Companies such as 3SBio Inc. and BioCryst Pharmaceuticals, Inc. have not only focused on advancing recombinant technologies but have also set industry benchmarks with continuous improvements in product quality and clinical efficacy. Organizations like Biosynth Ltd and Creative Enzymes are recognized for their state-of-the-art manufacturing capabilities, which have contributed to more cost-effective production models.

Other influential entities, including CUSABIO TECHNOLOGY LLC and GenScript Biotech Corporation, have forged strategic alliances that enhance research capabilities, enabling rapid progression from clinical trials to market approval. Hzymes Biotech, Innovent Biologics, Inc., and Kikkoman Corporation are also prominent due to their commitment to rigorous quality standards and innovative product development. The roles of Merck KGaA, OYC Americas, Inc., Protalix BioTherapeutics, Sisco Research Laboratories Pvt. Ltd., and Swedish Orphan Biovitrum AB further consolidate the market's competitive framework, positioning these companies as pioneers in the continuous evolution of therapeutic enzyme applications across multiple disease states.

The report delves into recent significant developments in the Recombinant Uricase Market, highlighting leading vendors and their innovative profiles. These include 3SBio Inc., BioCryst Pharmaceuticals, Inc., Biosynth Ltd, Creative Enzymes, CUSABIO TECHNOLOGY LLC, GenScript Biotech Corporation, Hzymes Biotech, Innovent Biologics, Inc., Kikkoman Corporation, Merck KGaA, OYC Americas, Inc., Protalix BioTherapeutics, Sisco Research Laboratories Pvt. Ltd., and Swedish Orphan Biovitrum AB.

Actionable Recommendations for Industry Leaders

Leaders looking to capitalize on the growth and diversification of the recombinant uricase market should consider several immediate strategic initiatives. First, investing in advanced process development and production technologies is critical; leveraging innovations in biotechnology can lead to not only improved product performance but also reduced manufacturing costs. Embracing partnerships with academic institutions and research consortia will further accelerate the development of next-generation therapeutics tailored to specific patient needs.

A key recommendation is to foster innovation within product development pipelines by focusing on both the diversification of formulations and the refinement of administration routes. Given the differentiated performance observed across biosimilars, non-pegylated, and pegylated products, aligning R&D strategies to these nuances can result in better market positioning. In addition, integrating comprehensive market segmentation insights into business planning is essential. By understanding the variances in application-based and end-user needs, companies can tailor clinical protocols and patient support programs to boost overall treatment efficacy and patient adherence.

To maintain competitive advantage, it is also necessary to monitor regional market trends and adapt to local regulatory environments. Companies are encouraged to develop flexible strategies that incorporate both global best practices and local market insights. Finally, robust post-market surveillance and continuous feedback loops will help refine products in real-time, ensuring that therapeutic offerings remain both innovative and clinically relevant. These strategic initiatives are designed to secure a resilient foothold in a rapidly evolving market landscape.

In summary, the recombinant uricase market stands at the confluence of advanced biotechnological innovation and shifting healthcare imperatives. The analysis captures a thorough perspective on market segmentation that ranges from advanced product types and administration routes to detailed applications and specific end-user needs. This comprehensive exploration reveals that the dynamics of the market are shaped by not only technological breakthroughs but also by regional and competitive factors influencing industry strategies.

A clear understanding of transformative shifts, detailed segmentation assessments, and regional as well as corporate insights create a panoramic view that enables firms to navigate this competitive sector effectively. Strategic investments in process innovation and market-focused research remain critical to addressing the evolving needs of diverse patient populations. Ultimately, this review underscores the need for industry players to adopt a proactive and agile approach, ensuring that they can harness emerging opportunities while meeting future clinical and commercial challenges head-on.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increasing prevalence of gout and hyperuricemia worldwide
5.1.1.2. Growing awareness of targeted therapies and personalized medicine approaches
5.1.1.3. Expansion of patient population, novel drug formulations, and supportive regulatory frameworks
5.1.2. Restraints
5.1.2.1. High cost of recombinant uricase therapies
5.1.3. Opportunities
5.1.3.1. Development of novel uricase therapies with improved efficacy and safety profiles
5.1.3.2. Increasing regulatory incentives, including orphan drug status, encouraging innovation
5.1.4. Challenges
5.1.4.1. Potential for adverse reactions and the development of anti-drug antibodies
5.2. Market Segmentation Analysis
5.2.1. Product Type : High preference for non-pegylated uricase in acute care settings requiring swift management of complicated gout and hyperuricemia
5.2.2. Application : Significant adoption of gout treatment due to the ongoing need for practical solutions managing elevated uric acid levels
5.3. Porter’s Five Forces Analysis
5.3.1. Threat of New Entrants
5.3.2. Threat of Substitutes
5.3.3. Bargaining Power of Customers
5.3.4. Bargaining Power of Suppliers
5.3.5. Industry Rivalry
5.4. PESTLE Analysis
5.4.1. Political
5.4.2. Economic
5.4.3. Social
5.4.4. Technological
5.4.5. Legal
5.4.6. Environmental
6. Recombinant Uricase Market, by Product Type
6.1. Introduction
6.2. Biosimilars of Recombinant Uricase
6.3. Non-Pegylated Uricase
6.4. Pegylated Uricase
7. Recombinant Uricase Market, by Route Of Administration
7.1. Introduction
7.2. Intramuscular
7.3. Intravenous
7.4. Subcutaneous
8. Recombinant Uricase Market, by Application
8.1. Introduction
8.2. Cancer Treatment
8.3. Gout Treatment
8.3.1. Chronic Gout
8.3.2. Hyperuricemia
8.3.3. Refractory Gout
8.3.4. Tumor Lysis Syndrome
8.4. Kidney Diseases
8.5. Neurological Disorders
8.6. Rare Genetic Disorders
9. Recombinant Uricase Market, by End-User
9.1. Introduction
9.2. Healthcare Providers
9.2.1. Clinics
9.2.2. Dialysis Centers
9.2.3. Hospitals
9.3. Pharmaceutical Manufacturers
9.4. Research & Development Institutes
10. Americas Recombinant Uricase Market
10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States
11. Asia-Pacific Recombinant Uricase Market
11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand
11.13. Vietnam
12. Europe, Middle East & Africa Recombinant Uricase Market
12.1. Introduction
12.2. Denmark
12.3. Egypt
12.4. Finland
12.5. France
12.6. Germany
12.7. Israel
12.8. Italy
12.9. Netherlands
12.10. Nigeria
12.11. Norway
12.12. Poland
12.13. Qatar
12.14. Russia
12.15. Saudi Arabia
12.16. South Africa
12.17. Spain
12.18. Sweden
12.19. Switzerland
12.20. Turkey
12.21. United Arab Emirates
12.22. United Kingdom
13. Competitive Landscape
13.1. Market Share Analysis, 2024
13.2. FPNV Positioning Matrix, 2024
13.3. Competitive Scenario Analysis
13.3.1. Protalix BioTherapeutics receives USD 20 million milestone to fuel pipeline expansion
13.3.2. Protalix BioTherapeutics launches a phase I first-in-human trial evaluating PRX-115
13.4. Strategy Analysis & Recommendation
List of Figures
FIGURE 1. RECOMBINANT URICASE MARKET MULTI-CURRENCY
FIGURE 2. RECOMBINANT URICASE MARKET MULTI-LANGUAGE
FIGURE 3. RECOMBINANT URICASE MARKET RESEARCH PROCESS
FIGURE 4. RECOMBINANT URICASE MARKET SIZE, 2024 VS 2030
FIGURE 5. GLOBAL RECOMBINANT URICASE MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 6. GLOBAL RECOMBINANT URICASE MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL RECOMBINANT URICASE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 8. GLOBAL RECOMBINANT URICASE MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
FIGURE 9. GLOBAL RECOMBINANT URICASE MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 10. GLOBAL RECOMBINANT URICASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 11. GLOBAL RECOMBINANT URICASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 12. GLOBAL RECOMBINANT URICASE MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
FIGURE 13. GLOBAL RECOMBINANT URICASE MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 14. GLOBAL RECOMBINANT URICASE MARKET SIZE, BY END-USER, 2024 VS 2030 (%)
FIGURE 15. GLOBAL RECOMBINANT URICASE MARKET SIZE, BY END-USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 16. AMERICAS RECOMBINANT URICASE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 17. AMERICAS RECOMBINANT URICASE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 18. UNITED STATES RECOMBINANT URICASE MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 19. UNITED STATES RECOMBINANT URICASE MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 20. ASIA-PACIFIC RECOMBINANT URICASE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 21. ASIA-PACIFIC RECOMBINANT URICASE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA RECOMBINANT URICASE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 23. EUROPE, MIDDLE EAST & AFRICA RECOMBINANT URICASE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 24. RECOMBINANT URICASE MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 25. RECOMBINANT URICASE MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. RECOMBINANT URICASE MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL RECOMBINANT URICASE MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL RECOMBINANT URICASE MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL RECOMBINANT URICASE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. RECOMBINANT URICASE MARKET DYNAMICS
TABLE 7. GLOBAL RECOMBINANT URICASE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL RECOMBINANT URICASE MARKET SIZE, BY BIOSIMILARS OF RECOMBINANT URICASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL RECOMBINANT URICASE MARKET SIZE, BY NON-PEGYLATED URICASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL RECOMBINANT URICASE MARKET SIZE, BY PEGYLATED URICASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL RECOMBINANT URICASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL RECOMBINANT URICASE MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL RECOMBINANT URICASE MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL RECOMBINANT URICASE MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL RECOMBINANT URICASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL RECOMBINANT URICASE MARKET SIZE, BY CANCER TREATMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL RECOMBINANT URICASE MARKET SIZE, BY GOUT TREATMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL RECOMBINANT URICASE MARKET SIZE, BY CHRONIC GOUT, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL RECOMBINANT URICASE MARKET SIZE, BY HYPERURICEMIA, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL RECOMBINANT URICASE MARKET SIZE, BY REFRACTORY GOUT, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL RECOMBINANT URICASE MARKET SIZE, BY TUMOR LYSIS SYNDROME, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL RECOMBINANT URICASE MARKET SIZE, BY GOUT TREATMENT, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL RECOMBINANT URICASE MARKET SIZE, BY KIDNEY DISEASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL RECOMBINANT URICASE MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL RECOMBINANT URICASE MARKET SIZE, BY RARE GENETIC DISORDERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL RECOMBINANT URICASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL RECOMBINANT URICASE MARKET SIZE, BY HEALTHCARE PROVIDERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL RECOMBINANT URICASE MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL RECOMBINANT URICASE MARKET SIZE, BY DIALYSIS CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL RECOMBINANT URICASE MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL RECOMBINANT URICASE MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL RECOMBINANT URICASE MARKET SIZE, BY PHARMACEUTICAL MANUFACTURERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL RECOMBINANT URICASE MARKET SIZE, BY RESEARCH & DEVELOPMENT INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. AMERICAS RECOMBINANT URICASE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 35. AMERICAS RECOMBINANT URICASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 36. AMERICAS RECOMBINANT URICASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 37. AMERICAS RECOMBINANT URICASE MARKET SIZE, BY GOUT TREATMENT, 2018-2030 (USD MILLION)
TABLE 38. AMERICAS RECOMBINANT URICASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 39. AMERICAS RECOMBINANT URICASE MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
TABLE 40. AMERICAS RECOMBINANT URICASE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 41. ARGENTINA RECOMBINANT URICASE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 42. ARGENTINA RECOMBINANT URICASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 43. ARGENTINA RECOMBINANT URICASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 44. ARGENTINA RECOMBINANT URICASE MARKET SIZE, BY GOUT TREATMENT, 2018-2030 (USD MILLION)
TABLE 45. ARGENTINA RECOMBINANT URICASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 46. ARGENTINA RECOMBINANT URICASE MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
TABLE 47. BRAZIL RECOMBINANT URICASE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 48. BRAZIL RECOMBINANT URICASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 49. BRAZIL RECOMBINANT URICASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 50. BRAZIL RECOMBINANT URICASE MARKET SIZE, BY GOUT TREATMENT, 2018-2030 (USD MILLION)
TABLE 51. BRAZIL RECOMBINANT URICASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 52. BRAZIL RECOMBINANT URICASE MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
TABLE 53. CANADA RECOMBINANT URICASE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 54. CANADA RECOMBINANT URICASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 55. CANADA RECOMBINANT URICASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 56. CANADA RECOMBINANT URICASE MARKET SIZE, BY GOUT TREATMENT, 2018-2030 (USD MILLION)
TABLE 57. CANADA RECOMBINANT URICASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 58. CANADA RECOMBINANT URICASE MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
TABLE 59. MEXICO RECOMBINANT URICASE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 60. MEXICO RECOMBINANT URICASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 61. MEXICO RECOMBINANT URICASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 62. MEXICO RECOMBINANT URICASE MARKET SIZE, BY GOUT TREATMENT, 2018-2030 (USD MILLION)
TABLE 63. MEXICO RECOMBINANT URICASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 64. MEXICO RECOMBINANT URICASE MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
TABLE 65. UNITED STATES RECOMBINANT URICASE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 66. UNITED STATES RECOMBINANT URICASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 67. UNITED STATES RECOMBINANT URICASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 68. UNITED STATES RECOMBINANT URICASE MARKET SIZE, BY GOUT TREATMENT, 2018-2030 (USD MILLION)
TABLE 69. UNITED STATES RECOMBINANT URICASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 70. UNITED STATES RECOMBINANT URICASE MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
TABLE 71. UNITED STATES RECOMBINANT URICASE MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 72. ASIA-PACIFIC RECOMBINANT URICASE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 73. ASIA-PACIFIC RECOMBINANT URICASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 74. ASIA-PACIFIC RECOMBINANT URICASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 75. ASIA-PACIFIC RECOMBINANT URICASE MARKET SIZE, BY GOUT TREATMENT, 2018-2030 (USD MILLION)
TABLE 76. ASIA-PACIFIC RECOMBINANT URICASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 77. ASIA-PACIFIC RECOMBINANT URICASE MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
TABLE 78. ASIA-PACIFIC RECOMBINANT URICASE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 79. AUSTRALIA RECOMBINANT URICASE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 80. AUSTRALIA RECOMBINANT URICASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 81. AUSTRALIA RECOMBINANT URICASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 82. AUSTRALIA RECOMBINANT URICASE MARKET SIZE, BY GOUT TREATMENT, 2018-2030 (USD MILLION)
TABLE 83. AUSTRALIA RECOMBINANT URICASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 84. AUSTRALIA RECOMBINANT URICASE MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
TABLE 85. CHINA RECOMBINANT URICASE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 86. CHINA RECOMBINANT URICASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 87. CHINA RECOMBINANT URICASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 88. CHINA RECOMBINANT URICASE MARKET SIZE, BY GOUT TREATMENT, 2018-2030 (USD MILLION)
TABLE 89. CHINA RECOMBINANT URICASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 90. CHINA RECOMBINANT URICASE MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
TABLE 91. INDIA RECOMBINANT URICASE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 92. INDIA RECOMBINANT URICASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 93. INDIA RECOMBINANT URICASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 94. INDIA RECOMBINANT URICASE MARKET SIZE, BY GOUT TREATMENT, 2018-2030 (USD MILLION)
TABLE 95. INDIA RECOMBINANT URICASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 96. INDIA RECOMBINANT URICASE MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
TABLE 97. INDONESIA RECOMBINANT URICASE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 98. INDONESIA RECOMBINANT URICASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 99. INDONESIA RECOMBINANT URICASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 100. INDONESIA RECOMBINANT URICASE MARKET SIZE, BY GOUT TREATMENT, 2018-2030 (USD MILLION)
TABLE 101. INDONESIA RECOMBINANT URICASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 102. INDONESIA RECOMBINANT URICASE MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
TABLE 103. JAPAN RECOMBINANT URICASE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 104. JAPAN RECOMBINANT URICASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 105. JAPAN RECOMBINANT URICASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 106. JAPAN RECOMBINANT URICASE MARKET SIZE, BY GOUT TREATMENT, 2018-2030 (USD MILLION)
TABLE 107. JAPAN RECOMBINANT URICASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 108. JAPAN RECOMBINANT URICASE MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
TABLE 109. MALAYSIA RECOMBINANT URICASE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 110. MALAYSIA RECOMBINANT URICASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 111. MALAYSIA RECOMBINANT URICASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 112. MALAYSIA RECOMBINANT URICASE MARKET SIZE, BY GOUT TREATMENT, 2018-2030 (USD MILLION)
TABLE 113. MALAYSIA RECOMBINANT URICASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 114. MALAYSIA RECOMBINANT URICASE MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
TABLE 115. PHILIPPINES RECOMBINANT URICASE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 116. PHILIPPINES RECOMBINANT URICASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 117. PHILIPPINES RECOMBINANT URICASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 118. PHILIPPINES RECOMBINANT URICASE MARKET SIZE, BY GOUT TREATMENT, 2018-2030 (USD MILLION)
TABLE 119. PHILIPPINES RECOMBINANT URICASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 120. PHILIPPINES RECOMBINANT URICASE MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
TABLE 121. SINGAPORE RECOMBINANT URICASE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 122. SINGAPORE RECOMBINANT URICASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 123. SINGAPORE RECOMBINANT URICASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 124. SINGAPORE RECOMBINANT URICASE MARKET SIZE, BY GOUT TREATMENT, 2018-2030 (USD MILLION)
TABLE 125. SINGAPORE RECOMBINANT URICASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 126. SINGAPORE RECOMBINANT URICASE MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
TABLE 127. SOUTH KOREA RECOMBINANT URICASE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 128. SOUTH KOREA RECOMBINANT URICASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 129. SOUTH KOREA RECOMBINANT URICASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 130. SOUTH KOREA RECOMBINANT URICASE MARKET SIZE, BY GOUT TREATMENT, 2018-2030 (USD MILLION)
TABLE 131. SOUTH KOREA RECOMBINANT URICASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 132. SOUTH KOREA RECOMBINANT URICASE MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
TABLE 133. TAIWAN RECOMBINANT URICASE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 134. TAIWAN RECOMBINANT URICASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 135. TAIWAN RECOMBINANT URICASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 136. TAIWAN RECOMBINANT URICASE MARKET SIZE, BY GOUT TREATMENT, 2018-2030 (USD MILLION)
TABLE 137. TAIWAN RECOMBINANT URICASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 138. TAIWAN RECOMBINANT URICASE MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
TABLE 139. THAILAND RECOMBINANT URICASE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 140. THAILAND RECOMBINANT URICASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 141. THAILAND RECOMBINANT URICASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 142. THAILAND RECOMBINANT URICASE MARKET SIZE, BY GOUT TREATMENT, 2018-2030 (USD MILLION)
TABLE 143. THAILAND RECOMBINANT URICASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 144. THAILAND RECOMBINANT URICASE MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
TABLE 145. VIETNAM RECOMBINANT URICASE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 146. VIETNAM RECOMBINANT URICASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 147. VIETNAM RECOMBINANT URICASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 148. VIETNAM RECOMBINANT URICASE MARKET SIZE, BY GOUT TREATMENT, 2018-2030 (USD MILLION)
TABLE 149. VIETNAM RECOMBINANT URICASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 150. VIETNAM RECOMBINANT URICASE MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
TABLE 151. EUROPE, MIDDLE EAST & AFRICA RECOMBINANT URICASE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 152. EUROPE, MIDDLE EAST & AFRICA RECOMBINANT URICASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 153. EUROPE, MIDDLE EAST & AFRICA RECOMBINANT URICASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 154. EUROPE, MIDDLE EAST & AFRICA RECOMBINANT URICASE MARKET SIZE, BY GOUT TREATMENT, 2018-2030 (USD MILLION)
TABLE 155. EUROPE, MIDDLE EAST & AFRICA RECOMBINANT URICASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 156. EUROPE, MIDDLE EAST & AFRICA RECOMBINANT URICASE MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
TABLE 157. EUROPE, MIDDLE EAST & AFRICA RECOMBINANT URICASE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 158. DENMARK RECOMBINANT URICASE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 159. DENMARK RECOMBINANT URICASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 160. DENMARK RECOMBINANT URICASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 161. DENMARK RECOMBINANT URICASE MARKET SIZE, BY GOUT TREATMENT, 2018-2030 (USD MILLION)
TABLE 162. DENMARK RECOMBINANT URICASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 163. DENMARK RECOMBINANT URICASE MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
TABLE 164. EGYPT RECOMBINANT URICASE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 165. EGYPT RECOMBINANT URICASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 166. EGYPT RECOMBINANT URICASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 167. EGYPT RECOMBINANT URICASE MARKET SIZE, BY GOUT TREATMENT, 2018-2030 (USD MILLION)
TABLE 168. EGYPT RECOMBINANT URICASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 169. EGYPT RECOMBINANT URICASE MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
TABLE 170. FINLAND RECOMBINANT URICASE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 171. FINLAND RECOMBINANT URICASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 172. FINLAND RECOMBINANT URICASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 173. FINLAND RECOMBINANT URICASE MARKET SIZE, BY GOUT TREATMENT, 2018-2030 (USD MILLION)
TABLE 174. FINLAND RECOMBINANT URICASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 175. FINLAND RECOMBINANT URICASE MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
TABLE 176. FRANCE RECOMBINANT URICASE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 177. FRANCE RECOMBINANT URICASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 178. FRANCE RECOMBINANT URICASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 179. FRANCE RECOMBINANT URICASE MARKET SIZE, BY GOUT TREATMENT, 2018-2030 (USD MILLION)
TABLE 180. FRANCE RECOMBINANT URICASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 181. FRANCE RECOMBINANT URICASE MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
TABLE 182. GERMANY RECOMBINANT URICASE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 183. GERMANY RECOMBINANT URICASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 184. GERMANY RECOMBINANT URICASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 185. GERMANY RECOMBINANT URICASE MARKET SIZE, BY GOUT TREATMENT, 2018-2030 (USD MILLION)
TABLE 186. GERMANY RECOMBINANT URICASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 187. GERMANY RECOMBINANT URICASE MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
TABLE 188. ISRAEL RECOMBINANT URICASE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 189. ISRAEL RECOMBINANT URICASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 190. ISRAEL RECOMBINANT URICASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 191. ISRAEL RECOMBINANT URICASE MARKET SIZE, BY GOUT TREATMENT, 2018-2030 (USD MILLION)
TABLE 192. ISRAEL RECOMBINANT URICASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 193. ISRAEL RECOMBINANT URICASE MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
TABLE 194. ITALY RECOMBINANT URICASE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 195. ITALY RECOMBINANT URICASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 196. ITALY RECOMBINANT URICASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 197. ITALY RECOMBINANT URICASE MARKET SIZE, BY GOUT TREATMENT, 2018-2030 (USD MILLION)
TABLE 198. ITALY RECOMBINANT URICASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 199. ITALY RECOMBINANT URICASE MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
TABLE 200. NETHERLANDS RECOMBINANT URICASE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 201. NETHERLANDS RECOMBINANT URICASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 202. NETHERLANDS RECOMBINANT URICASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 203. NETHERLANDS RECOMBINANT URICASE MARKET SIZE, BY GOUT TREATMENT, 2018-2030 (USD MILLION)
TABLE 204. NETHERLANDS RECOMBINANT URICASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 205. NETHERLANDS RECOMBINANT URICASE MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
TABLE 206. NIGERIA RECOMBINANT URICASE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 207. NIGERIA RECOMBINANT URICASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 208. NIGERIA RECOMBINANT URICASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 209. NIGERIA RECOMBINANT URICASE MARKET SIZE, BY GOUT TREATMENT, 2018-2030 (USD MILLION)
TABLE 210. NIGERIA RECOMBINANT URICASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 211. NIGERIA RECOMBINANT URICASE MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
TABLE 212. NORWAY RECOMBINANT URICASE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 213. NORWAY RECOMBINANT URICASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 214. NORWAY RECOMBINANT URICASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 215. NORWAY RECOMBINANT URICASE MARKET SIZE, BY GOUT TREATMENT, 2018-2030 (USD MILLION)
TABLE 216. NORWAY RECOMBINANT URICASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 217. NORWAY RECOMBINANT URICASE MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
TABLE 218. POLAND RECOMBINANT URICASE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 219. POLAND RECOMBINANT URICASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 220. POLAND RECOMBINANT URICASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 221. POLAND RECOMBINANT URICASE MARKET SIZE, BY GOUT TREATMENT, 2018-2030 (USD MILLION)
TABLE 222. POLAND RECOMBINANT URICASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 223. POLAND RECOMBINANT URICASE MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
TABLE 224. QATAR RECOMBINANT URICASE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 225. QATAR RECOMBINANT URICASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 226. QATAR RECOMBINANT URICASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 227. QATAR RECOMBINANT URICASE MARKET SIZE, BY GOUT TREATMENT, 2018-2030 (USD MILLION)
TABLE 228. QATAR RECOMBINANT URICASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 229. QATAR RECOMBINANT URICASE MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
TABLE 230. RUSSIA RECOMBINANT URICASE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 231. RUSSIA RECOMBINANT URICASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 232. RUSSIA RECOMBINANT URICASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 233. RUSSIA RECOMBINANT URICASE MARKET SIZE, BY GOUT TREATMENT, 2018-2030 (USD MILLION)
TABLE 234. RUSSIA RECOMBINANT URICASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 235. RUSSIA RECOMBINANT URICASE MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
TABLE 236. SAUDI ARABIA RECOMBINANT URICASE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 237. SAUDI ARABIA RECOMBINANT URICASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 238. SAUDI ARABIA RECOMBINANT URICASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 239. SAUDI ARABIA RECOMBINANT URICASE MARKET SIZE, BY GOUT TREATMENT, 2018-2030 (USD MILLION)
TABLE 240. SAUDI ARABIA RECOMBINANT URICASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 241. SAUDI ARABIA RECOMBINANT URICASE MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
TABLE 242. SOUTH AFRICA RECOMBINANT URICASE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 243. SOUTH AFRICA RECOMBINANT URICASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 244. SOUTH AFRICA RECOMBINANT URICASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 245. SOUTH AFRICA RECOMBINANT URICASE MARKET SIZE, BY GOUT TREATMENT, 2018-2030 (USD MILLION)
TABLE 246. SOUTH AFRICA RECOMBINANT URICASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 247. SOUTH AFRICA RECOMBINANT URICASE MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
TABLE 248. SPAIN RECOMBINANT URICASE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 249. SPAIN RECOMBINANT URICASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 250. SPAIN RECOMBINANT URICASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 251. SPAIN RECOMBINANT URICASE MARKET SIZE, BY GOUT TREATMENT, 2018-2030 (USD MILLION)
TABLE 252. SPAIN RECOMBINANT URICASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 253. SPAIN RECOMBINANT URICASE MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
TABLE 254. SWEDEN RECOMBINANT URICASE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 255. SWEDEN RECOMBINANT URICASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 256. SWEDEN RECOMBINANT URICASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 257. SWEDEN RECOMBINANT URICASE MARKET SIZE, BY GOUT TREATMENT, 2018-2030 (USD MILLION)
TABLE 258. SWEDEN RECOMBINANT URICASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 259. SWEDEN RECOMBINANT URICASE MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
TABLE 260. SWITZERLAND RECOMBINANT URICASE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 261. SWITZERLAND RECOMBINANT URICASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 262. SWITZERLAND RECOMBINANT URICASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 263. SWITZERLAND RECOMBINANT URICASE MARKET SIZE, BY GOUT TREATMENT, 2018-2030 (USD MILLION)
TABLE 264. SWITZERLAND RECOMBINANT URICASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 265. SWITZERLAND RECOMBINANT URICASE MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
TABLE 266. TURKEY RECOMBINANT URICASE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 267. TURKEY RECOMBINANT URICASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 268. TURKEY RECOMBINANT URICASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 269. TURKEY RECOMBINANT URICASE MARKET SIZE, BY GOUT TREATMENT, 2018-2030 (USD MILLION)
TABLE 270. TURKEY RECOMBINANT URICASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 271. TURKEY RECOMBINANT URICASE MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
TABLE 272. UNITED ARAB EMIRATES RECOMBINANT URICASE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 273. UNITED ARAB EMIRATES RECOMBINANT URICASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 274. UNITED ARAB EMIRATES RECOMBINANT URICASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 275. UNITED ARAB EMIRATES RECOMBINANT URICASE MARKET SIZE, BY GOUT TREATMENT, 2018-2030 (USD MILLION)
TABLE 276. UNITED ARAB EMIRATES RECOMBINANT URICASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 277. UNITED ARAB EMIRATES RECOMBINANT URICASE MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
TABLE 278. UNITED KINGDOM RECOMBINANT URICASE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 279. UNITED KINGDOM RECOMBINANT URICASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 280. UNITED KINGDOM RECOMBINANT URICASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 281. UNITED KINGDOM RECOMBINANT URICASE MARKET SIZE, BY GOUT TREATMENT, 2018-2030 (USD MILLION)
TABLE 282. UNITED KINGDOM RECOMBINANT URICASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 283. UNITED KINGDOM RECOMBINANT URICASE MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
TABLE 284. RECOMBINANT URICASE MARKET SHARE, BY KEY PLAYER, 2024
TABLE 285. RECOMBINANT URICASE MARKET, FPNV POSITIONING MATRIX, 2024

Companies Mentioned

  • 3SBio Inc.
  • BioCryst Pharmaceuticals, Inc.
  • Biosynth Ltd
  • Creative Enzymes
  • CUSABIO TECHNOLOGY LLC
  • GenScript Biotech Corporation
  • Hzymes Biotech
  • Innovent Biologics, Inc.
  • Kikkoman Corporation
  • Merck KGaA
  • OYC Americas, Inc.
  • Protalix BioTherapeutics
  • Sisco Research Laboratories Pvt. Ltd.
  • Swedish Orphan Biovitrum AB

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages181
PublishedMarch 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 1.53 Billion
Forecasted Market Value ( USD ) by 2030 $ 2.04 Billion
Compound Annual Growth Rate5.9%
Regions CoveredGlobal
No. of Companies Mentioned14

Related Topics

Related Reports

Hyperuricemia Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034 - Product Image

Hyperuricemia Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

  • Report
  • 140 Pages
  • Global
From
Recombinant Cell Culture Supplements Market by Product Type (Recombinant Albumin, Recombinant Aprotinin, Recombinant Growth Factors), Source (Animal-derived Supplements, Human-derived Supplements), Application, End-Users - Global Forecast 2025-2030 - Product Image

Recombinant Cell Culture Supplements Market by Product Type (Recombinant Albumin, Recombinant Aprotinin, Recombinant Growth Factors), Source (Animal-derived Supplements, Human-derived Supplements), Application, End-Users - Global Forecast 2025-2030

  • Report
  • 189 Pages
  • Global
From
Biosimilars Market by Product, Indication, Manufacturing - Global Forecast 2025-2030 - Product Image

Biosimilars Market by Product, Indication, Manufacturing - Global Forecast 2025-2030

  • Report
  • 187 Pages
  • Global
From
Recombinant Proteins Market Size, Share & Trends Analysis Report by Product (Cytokines & Growth Factors, Antibodies), Application (Therapeutics), End-use, Host Cell (Mammalian), Region, and Segment Forecasts, 2025-2030 - Product Image

Recombinant Proteins Market Size, Share & Trends Analysis Report by Product (Cytokines & Growth Factors, Antibodies), Application (Therapeutics), End-use, Host Cell (Mammalian), Region, and Segment Forecasts, 2025-2030

  • Report
  • 120 Pages
  • Global
From
Recombinant Cell Culture Supplements Market Size, Share & Trends Analysis Report By Products (Recombinant Albumin, Recombinant Insulin), By Application, By, Type, By End-use, By Region, And Segment Forecasts, 2025 - 2033 - Product Image

Recombinant Cell Culture Supplements Market Size, Share & Trends Analysis Report By Products (Recombinant Albumin, Recombinant Insulin), By Application, By, Type, By End-use, By Region, And Segment Forecasts, 2025 - 2033

  • Report
  • 120 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.